e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Medicenna Thera Corp
(OP:
MDNAF
)
0.1250
-0.0350 (-21.88%)
Delayed Quote
Updated: 3:58 PM EST, Nov 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Medicenna Thera Corp
< Previous
1
2
Next >
Medicenna Announces Results of Annual Meeting of Shareholders
September 25, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
September 05, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
August 01, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
July 31, 2025
Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation...
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
June 26, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
↗
June 13, 2025
Via
Stocktwits
Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting
April 30, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
April 28, 2025
From
Medicenna Therapeutics Corp.
Via
GlobeNewswire
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
October 15, 2024
From
OTC Markets
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.